Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pharmaceuticals (Basel) ; 16(8)2023 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-37631043

RESUMO

The microbiome of the colon is characterized by its great diversity. This varies not only intra- but also interindividually and is influenced by endogenous and exogenous factors, such as dietary and lifestyle factors. The aim of this work was to investigate the extent to which the degradation of the drug sulfasalazine is influenced by different microbiota. Therefore, the in vitro model MimiCol3 was used, which represents the physiological conditions of the ascending colon. In addition to a representative physiological volume, the pH value, redox potential and an anaerobic atmosphere are important to provide the bacteria with the best possible growth conditions. Stool samples were taken from three healthy subjects, comparing omnivorous, vegetarian and meat-rich diets, and cultured for 24 h. However, the nutrient medium used for cultivation led to the alignment of the bacterial composition of the microbiota. The previously observed differences between the diets could not be maintained. Nevertheless, the similar degradation of sulfasalazine was observed in all microbiota studied in MimiCol3. This makes MimiCol3 a suitable in vitro model for metabolism studies in the gut microbiome.

2.
Pharmaceutics ; 14(5)2022 May 13.
Artigo em Inglês | MEDLINE | ID: mdl-35631635

RESUMO

In recent years, the colon has become a hot topic in biopharmaceutical research as several in vitro models of the human colon have been presented. A major focus is on the characterization of the microbiota and its capabilities. The aim of the present study was to further develop the MimiCol, preserving its properties and accelerating data acquisition. Emphasis was placed on the simplicity of its design and easy scalability. To prove the viability of the concept, degradation of sulfasalazine was investigated, and the bacterial composition during the experiment was assessed by 16S rRNA sequencing. The transfer of the experimental conditions to the new model was successful. Commercially available components were implemented in the setup. The model MimiCol3 represented the colon ascendens satisfactorily in its properties regarding volume, pH value, and redox potential. 16S rRNA sequencing led to further insights into the bacterial composition in the vessels. Degradation of sulfasalazine was in good agreement with in vivo data. The new model of the colon ascendens MimiCol3 enabled us to collect more reliable data, as three experiments were conducted simultaneously under the same conditions.

3.
Int J Pharm ; 603: 120704, 2021 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-33991596

RESUMO

Due to the potential effects of colonic metabolism, the interest in the composition and action of intestinal microbiota has increased significantly throughout the last 10 years. Recently focus is turning to the development and implementation of in vitro tools closely simulating in vivo colonic metabolic processes suitable for routine use. The aim of the present study is to compare the metabolization of the model drug sulfasalazine utilizing the novel dynamic bioreactor MimiCol and a standard static batch fermenter inoculated with cryopreserved faecal microbiota. Major advantages of the novel bioreactor MimiCol are the smaller media volume which is closer to in vivo conditions, the possibility to perform media changes and the closer simulation of in vivo mixing patterns. The study proved that the MimiCol is able to simulate the dynamic conditions found within the ascending colon. The dynamic conditions within the MimiCol led to an almost 2-fold increase of the metabolization rate constant in comparison to the static batch fermenter. Our study was able to prove that the novel dynamic bioreactor MimiCol is able to closely simulate physiologically relevant conditions.


Assuntos
Microbioma Gastrointestinal , Microbiota , Colo , Sulfassalazina , Xenobióticos
4.
Eur J Pharm Sci ; 107: 71-77, 2017 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-28673756

RESUMO

Novel in vitro dissolution tools can aid the development of orally administered drugs by explaining dosage form related in vivo phenomena that are not explainable with standard test apparatuses. Such novel tools are able to mimic various parameters in accordance with gastrointestinal conditions. Hereby, in vivo occurring pressure events were shown to be of major importance since they largely affect dosage form disintegration, drug dissolution and subsequently resulting drug plasma concentration profiles. The aim of the present study was to investigate the feasibility of producing biorelevant pressure events with standard test apparatuses and with the dynamic open flow through test apparatus. For this purpose, we used the SmartPill®, a swallowable capsule that houses a pressure sensor and that was already applied to gather human in vivo data. Among the standard apparatuses, highest pressures were measured in the reciprocating cylinder apparatus and the disintegration tester. No relevant pressure peaks could be detected in the paddle apparatus and the mini paddle apparatus. In contrast, the dynamic open flow through test apparatus enabled the simulation of complete gastric pressure profiles as they occur in vivo. The present work underlines the potential of novel in vitro dissolution models as useful tools during the drug development process as well as for explanatory purposes.


Assuntos
Cápsulas , Liberação Controlada de Fármacos , Pressão , Estômago , Telemetria , Jejum , Trânsito Gastrointestinal , Humanos , Concentração de Íons de Hidrogênio , Software , Estômago/química , Tecnologia Farmacêutica , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...